NMDA channel blockers: Memantine and amino-aklylcyclohexanes - In vivo characterization

Amino Acids

Volumn 19, Issue 1, 2000, Pages 167-172

  Danysz, W ^a   Parsons, C G ^a   Quack, G ^a  

^a Merz+Co ^*  (Germany)

Author keywords

Amino acids; Channel blockers; Memantine; NMDA

Indexed keywords

AMINO AKLYLCYCLOHEXANE DERIVATIVE; DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; DRUG SCREENING; MICRODIALYSIS; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; CYCLOHEXANES; EXCITATORY AMINO ACID ANTAGONISTS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033806044     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007260070045     Document Type: Review

References (21)

1. Antidepressant effects of ketamine in depressed patients
2. Effects of NMDA receptor antagonists on reinforced and non-reinforced responding for ethanol in rats
3. Memantine attenuates withdrawal symptoms in morphine-maintained humans
4. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation
5. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? case of amantadine and memantine
6. The effects of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats
7. Ethanol and neurotransmitter interactions - From molecular to integrative effects
8. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal - Medication development issues for opiate addiction
9. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: A quantitative microdialysis study
10. Evidence for alcohol anti-craving properties of memantine
11. The novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to the ethanol cue in a drug discrimination procedure
12. MRZ 2/579, a fast kinetic NMDA channel blocker, delays the development of morphine tolerance in awake rats
13. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease - Comparison with uncompetitive NMDA receptor antagonists
14. The phencyclidine (PCP) analog N-[1-(2-benzo(B)tiophenyl)cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801
15. Mechanisms that may underly the behavioural effects of ethanol
16. Potential antidepressive properties of amantadine, memantine and bifemelane
17. Glutamate in CNS Disorders as a target for drug development. An update
18. Memantine is a clinically well tolerated NMDA receptor antagonist - A review of preclinical data
19. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone precipitated opioid withdrawal by NMDA receptor antagonist, memantine
20. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to analgesic effects of morphine in mice
21. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments